Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 5/20 | 0.34 |
| ▸ | F13A1 | P00488 | 4/20 | 0.34 |
| ▸ | TGM1 | P22735 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18425705 | 0.88 | GPR119 (0.44) | GPR119USP2SMN1; SMN2TGM2F13A1 | |
| SCHEMBL25657237 | 0.86 | GPR119 (0.39) | GPR119HTTNR1H2 | |
| SCHEMBL18424056 | 0.82 | NAMPT (0.41) | GPR119 | |
| SCHEMBL18465709 | 0.80 | HSD11B1 (0.37) | GPR119HTTSMN1; SMN2NR1H2 | |
| SCHEMBL18465824 | 0.77 | GPR119 (0.40) | GPR119TGM2F13A1TGM1NR1H2 | |
| SCHEMBL2262506 | 0.69 | ALDH1A1 (0.52) | GPR119HTTUSP2SMN1; SMN2 | |
| SCHEMBL25168185 | 0.68 | HTT (0.39) | HTTSMN1; SMN2 | |
| SCHEMBL217823 | 0.68 | GPR119 (0.42) | GPR119USP2SMN1; SMN2 | |
| SCHEMBL25174705 | 0.68 | HTT (0.36) | HTTUSP2 | |
| SCHEMBL7397405 | 0.68 | GPR119 (0.44) | GPR119USP2SMN1; SMN2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230147859-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230147859-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC6, HDAC1, HDAC2 | GPR119 2091/4885HTT 93/4885USP2 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.